Yttrium-90 ibritumomab tiuxetan with high-dose carmustine, cytarabine, etoposide, and melphalan (Zevalin-BEAM) conditioning regimen in relapsed aggressive non-Hodgkin lymphoma

被引：0
|
作者：
Tan, S. M. [1 ]
Lau, N. S. [1 ]
Lim, S. M. [1 ]
Zanapiah, M. [1 ]
Chang, K. M. [1 ]
机构：
[1] Hosp Ampang, Ampang, Myanmar
来源：
BONE MARROW TRANSPLANTATION | 2008年 / 41卷
关键词：
D O I：
暂无
中图分类号：
Q6 [生物物理学];
学科分类号：
071011 ;
摘要：
引用
收藏
页码：S440 / S441
页数：2
相关论文
共 50 条
  • [31] Yttrium 90 ibritumomab tiuxetan radioimmunotherapy for relapsed or refractory low-grade non-Hodgkin's lymphoma
    Gordon, LI
    Witzig, TE
    Wiseman, GA
    Flinn, IW
    Spies, SS
    Silverman, DH
    Emmanuolides, C
    Cripe, L
    Saleh, M
    Czuczman, MS
    Olejnik, T
    White, CA
    Grillo-López, AJ
    SEMINARS IN ONCOLOGY, 2002, 29 (01) : 87 - 92
  • [32] A phase 1/2 trial of high-dose yttrium-90-ibritumomab tiuxetan in combination with high-dose etoposide and cyclophosphamide followed by autologous stem cell transplantation in patients with poor-risk or relapsed non-Hodgkin lymphoma
    Nademanee, A
    Forman, S
    Molina, A
    Fung, H
    Smith, D
    Dagis, A
    Kwok, C
    Yamauchi, D
    Anderson, AL
    Falk, P
    Krishnan, A
    Kirschbaum, M
    Kogut, N
    Nakamura, R
    O'Donnell, M
    Parker, P
    Popplewell, L
    Pullarkat, V
    Rodriguez, R
    Sahebi, F
    Smith, E
    Snyder, D
    Stein, A
    Spielberger, R
    Zain, J
    White, C
    Raubitschek, A
    BLOOD, 2005, 106 (08) : 2896 - 2902
  • [33] Subsequent chemotherapy regimens are well tolerated after radioimmunotherapy with yttrium-90 ibritumomab tiuxetan for non-Hodgkin's lymphoma
    Ansell, SM
    Ristow, KM
    Habermann, TM
    Wiseman, GA
    Witzig, TE
    JOURNAL OF CLINICAL ONCOLOGY, 2002, 20 (18) : 3885 - 3890
  • [34] Yttrium-90 (Ytracis) Labelled Ibritumomab Tiuxetan (Zevalin) in Patients with Relapsed or Refractory B-Cell non-Hodkin's Lymphoma
    Lipp, R. W.
    Piswanger-Soelkner, J. C.
    Dorda, A. F.
    Brezinschek, R. I.
    Lackner, H.
    Linkesch, W.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2005, 32 : S93 - S93
  • [35] Phase I/II 90Y-Zevalin (yttrium-90 ibritumomab tiuxetan, IDEC-Y2B8) radioimmunotherapy dosimetry results in relapsed or refractory non-Hodgkin's lymphoma
    Wiseman, GA
    White, CA
    Stabin, M
    Dunn, WL
    Erwin, W
    Dahlbom, M
    Raubitschek, A
    Karvelis, K
    Schultheiss, T
    Witzig, TE
    Belanger, R
    Spies, S
    Silverman, DHS
    Berlfein, JR
    Ding, E
    Grillo-Lópezs, AJ
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE, 2000, 27 (07) : 766 - 777
  • [36] Phase I/II 90Y-Zevalin (yttrium-90 ibritumomab tiuxetan, IDEC-Y2B8) radioimmunotherapy dosimetry results in relapsed or refractory non-Hodgkin’s lymphoma
    Gregory A. Wiseman
    Christine A. White
    Michael Stabin
    William L. Dunn
    William Erwin
    Magnus Dahlbom
    Andrew Raubitschek
    Kastytis Karvelis
    Timothy Schultheiss
    Thomas E. Witzig
    Richard Belanger
    Stewart Spies
    Daniel H. S. Silverman
    Judy R. Berlfein
    Eric Ding
    Antonio J. Grillo-López
    European Journal of Nuclear Medicine, 2000, 27 : 766 - 777
  • [37] Feasibility of yttrium 90 (90Y) ibritumomab tiuxetan (Zevalin®) radioimmunotherapy for non-Hodgkin's lymphoma in a patient with chronic renal failure.
    Spies, SM
    Gordon, LI
    Zimmer, AM
    Cutrera, P
    BLOOD, 2004, 104 (11) : 244B - 244B
  • [38] Assessment of Metabolic Response to Radioimmunotherapy (RIT) with Yttrium-90 (Y-90) Ibritumomab Tiuxetan in Patients with Relapsed or Refractory B-cell non-Hodgkin Lymphoma
    Storto, G.
    Nardelli, A.
    Pellegrino, T.
    Perna, F.
    De Falco, T.
    Erra, P.
    Ortosecco, G.
    Castaldi, E.
    Speranza, A.
    Klain, M.
    De Renzo, A.
    di Nuzzo, C.
    Pace, L.
    Rotoli, B.
    Salvatore, M.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2008, 35 : S148 - S148
  • [39] Yttrium-90 Ibritumomab Tiuxetan Doses Calculated to Deliver up to 15 Gy to Critical Organs May Be Safely Combined With High-Dose BEAM and Autologous Transplantation in Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma
    Winter, Jane N.
    Inwards, David J.
    Spies, Stewart
    Wiseman, Gregory
    Patton, David
    Erwin, William
    Rademaker, Alfred W.
    Weitner, Bing Bing
    Williams, Stephanie F.
    Tallman, Martin S.
    Micallef, Ivana
    Mehta, Jayesh
    Singhal, Seema
    Evens, Andrew M.
    Zimmer, Michael
    Molina, Arturo
    White, Christine A.
    Gordon, Leo I.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (10) : 1653 - 1659
  • [40] Autologous Stem Cell Transplantation with Bendaeam (Bendamustine, Etoposide, Cytarabine, Melphalan) As Conditioning Regimen for Non-Hodgkin's Lymphoma and Hodgkin's Lymphoma
    Garciaz, Sylvain
    Coso, Diane
    Broussais, Florence
    Schiano, Jean-Marc
    Calmels, Boris
    Saillard, Colombe
    Boudin, Lauris
    Amrane, Sophie
    Blaise, Didier
    Bouabdallah, Reda
    BLOOD, 2014, 124 (21)
12345